Maximus Review: An FDA Letter It Answered, and a Study It Ran Itself

The study Maximus ran on itself

Oxytocin Calming Cream is the newest thing here and the most heavily promoted: a once-daily topical oxytocin, $99 for a first month and $199 after, sold to "reduce stress, improve sleep, and lift mood—without next-day brain fog."

Under the claims sits a citation. Not to a journal — to Maximus.

Maximus Internal Study (N=152)

71% of study participants felt happier · 69% slept better · +25 min average additional rest per night · 0% reported morning fog

The paper behind those numbers is published on maximustribe.com, authored by Maximus's Scientific Director, its CEO and a colleague. It is not in a journal. A PubMed author search on 9 August 2026 returned zero indexed publications from those authors on these topics, and a ClinicalTrials.gov sponsor search for "Maximus" returned three studies, none of them this company's. ^{3 5}

That is not disqualifying on its own. Plenty of useful work sits outside journals. What matters is what the document says about itself, and this one is unusually candid — which is what makes reading it worthwhile.

What the paper concedes

There was no control group. From the Limitations: "This was an open-label study without a placebo control, so expectancy effects cannot be completely ruled out." Every outcome is a self-reported questionnaire score — sleep, mood, anxiety — in a field where expectancy is the central methodological problem rather than a footnote to it.

Nobody's oxytocin level was measured. The entire product premise is that a 1,007-dalton peptide crosses intact skin, against the "500 Dalton rule" the paper itself explains at length. Under Discussion: "Although direct pharmacokinetic confirmation was not obtained, the observed outcomes imply meaningful systemic activity."

The 12-to-16-hour window is not from oxytocin. The paper states that the absorption profile "is elucidated from pharmacokinetic data obtained with other molecules using this same transdermal base." The duration on the product page is inferred from a different drug in the same cream.

The headline percentages exclude the people it failed. From the Results: "Participants who worsened were excluded from this specific analysis to focus on the magnitude of benefit among responders."

"N=152" is not 152 people. From the Methods: "Because some individuals contributed data to both schedules, group Ns represent observation sets rather than unique individuals." The two arms are 86 and 66.

The dose sold is double the dose studied. Participants applied 500 IU daily. The marketed product is 1000 IU, on the strength of a cohort the paper describes only as "an exploratory higher-dose cohort" that "produced stronger improvements… with no new safety concerns" — no numbers, no N, no table.

And then the Conclusion: this "establishes topical oxytocin as a breakthrough in peptide hormone delivery, successfully overcoming the 500 Dalton barrier through innovative formulation technology."

That is a pharmacokinetic conclusion drawn from mood scores, in a document that states four paragraphs earlier that no pharmacokinetics were obtained. Surrogates and outcomes are different objects, and here the paper has neither: it has a questionnaire standing in for a blood level.

What the registry says about topical oxytocin

Set the company's paper aside and ask what anyone else has shown.

As of 9 August 2026, a ClinicalTrials.gov search for oxytocin as an intervention combined with topical or transdermal returns nine studies. ³ Every one is intravaginal oxytocin for vulvovaginal atrophy in postmenopausal women, or an obstetric or spinal study. None is a transdermal formulation intended to reach the brain. None measures mood, stress or sleep.

In PubMed, oxytocin with transdermal or topical, restricted to randomised controlled trials, returns eleven records. ² The topical-oxytocin trials among them are the same vaginal-atrophy line of work — and one of them, a 2018 multicentre randomised trial in Climacteric, carries the PubMed publication type Retracted Publication. ⁴ That is worth flagging for its own sake: a citation's publication type is a field you can read, and it sometimes says the paper has been withdrawn.

Maximus's own white paper agrees with all of this, in its Background: traditional topical forms "worked on nearby tissues but never entered systemic circulation in measurable ways." The company correctly describes the state of the evidence and then asks the reader to accept that its cream is the exception, on questionnaire data alone.

The intranasal oxytocin literature is a different and much larger body of work, and it is not what is being sold here. A cream is not a spray, the routes are not interchangeable, and the paper's own framing depends on that being true.

Sermorelin, and a claim about what was studied

The growth-hormone protocol runs $299.99 a month, or $199.99 on a six-month plan, and sells two molecules: sermorelin and tesamorelin.

The sermorelin page's claim is carefully hedged and still checkable:

Sermorelin may support muscle mass, recovery, sleep quality, skin, and body composition. These are potential effects studied in clinical research, not guaranteed outcomes.

"May support" is a hedge about the effect. "Studied in clinical research" is a statement about the literature, and that one is either true or it is not.

As of 9 August 2026, a PubMed search for sermorelin restricted to the randomised-controlled-trial publication type returns 19 records. ⁶ The most recent was published in August 2005. ⁷ Read the full set and every one measures growth hormone secretion, growth in children, the response to a diagnostic challenge, or the interaction of GHRH with another agent. Not one measures sleep quality. Not one measures muscle mass, skin, or body composition.

The mechanism sentence beside it — "Growth hormone is released mainly during deep sleep" — is true. It is a fact about GH physiology, not a finding about this drug, and the page uses the first to carry the second. The secretagogue family needs reading one molecule at a time, and sermorelin's literature stopped before it reached any of these endpoints.

One more line from the same page, which sits oddly beside everything else Maximus does well:

Do I need lab testing to qualify for Sermorelin? No. Lab testing is not required to use Sermorelin.

The protocol's entire proposed mechanism runs pituitary → growth hormone → IGF-1. Maximus sells IGF-1 testing, markets "before & after IGF-1 testing" as one of its four trust pillars, and does not require the baseline.

Tesamorelin, and the word that is missing

Tesamorelin is the strong card in this hand and Maximus plays it almost right.

Its Q&A says: "The most well-documented effect is visceral adipose tissue (VAT) reduction… Tesamorelin has a clinical track record here that most peptides do not." True. The article even cites the right sources — the 2007 New England Journal of Medicine trial and FDA's clinical pharmacology review of NDA 22-505.

That trial randomised 412 patients to 2 mg of tesamorelin or placebo daily for 26 weeks; CT-measured visceral adipose tissue fell 15.2% on drug and rose 5.0% on placebo. ⁹ It is registered as NCT00123253, phase 3, completed. ¹⁰ The extension study, NCT00608023, ran 263 more. ¹¹

The word that appears in the title of the paper Maximus cites, and nowhere in its own product copy, is HIV. Both phase 3 trials enrolled patients with HIV-associated lipodystrophy. The approved product's label states the indication as "the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy", and under Limitations of Use: "EGRIFTA WR is not indicated for weight loss management as it has a weight neutral effect." ⁸

Maximus sells it as part of a protocol headlined "Reduce fat. Recover faster. Rejuvenate naturally."

There is a second problem on the same page, of a different kind. The comparison table ranks the three options against each other:

A head-to-head safety ranking is a trial result or it is an opinion. The page also states that "the risk of serious side effects is significantly lower than with synthetic growth hormone" — a comparative claim inferred from mechanism, which is how you generate a hypothesis rather than how you show one drug is safer than another.

The two pages that get it right

It would be easy to file Maximus with the rest of the category, and the GLP-1 side of the site will not let you.

Compounded semaglutide. The claim: "In clinical trials of GLP-1 medications, adults lost a mean of roughly 15% of body weight over about a year (STEP-1, Novo Nordisk; SURMOUNT-1, Eli Lilly). This is a study average, not a prediction of your personal result." STEP 1 randomised 1,961 adults and reported −14.9% against −2.4% on placebo at 68 weeks. ^{12 13} The trials are named, the number is the trial's number, and the disclaimer does the work a headline percentage needs. The page states in the same block as the price that the preparation "is not FDA-approved" — though, as always, the compounded preparation is not the trial drug, and no page says which pharmacy makes it.

Foundayo. This is the best-sourced product claim in this entire review set, and the reason takes a paragraph to explain.

Foundayo is orforglipron, approved by FDA and labelled by Eli Lilly. ¹⁴ The pivotal trial is ATTAIN-1, NCT05869903, phase 3, 3,127 participants, 72 weeks. ¹⁶ The published paper reports doses of 6, 12 and 36 mg and a highest-dose result of −11.2% against −2.1% placebo. ¹⁵ The approved label reports the same trial with tablet strengths of 0.8 to 17.2 mg and a highest-dose result of −11.1% against −2.1%.

Maximus quotes the label: "adults on the highest dose of Foundayo™ lost an average of 11.1% of their body weight (about 25 lb) — intent-to-treat — compared with 2.1% on placebo." It names the trial, the enrolment, the duration and the estimand. And then it publishes the other estimand too: "Among completers: 12.4% / 27.3 lb."

Publishing the intent-to-treat figure as the headline and the completer figure as a labelled secondary is the opposite of what this industry does. So is this sentence, on a site that sells peptides: "Orforglipron is a small-molecule compound, not a peptide. It survives stomach acid and digestive enzymes without an absorption enhancer." That is exactly right, and it is the reason an oral GLP-1 pill exists at all.

The company that wrote the PCAC explainer

One last thing, because it is the strongest signal in either direction.

In June 2026 Maximus published an article by its Scientific Director explaining the Pharmacy Compounding Advisory Committee — what it is, what it advises on, and what was on its July 2026 agenda. The article names the peptides under review: BPC-157, KPV, TB-500, MOTS-c, DSIP, Semax and Epitalon-related substances. It states the rule correctly: a 503A compounder may use a bulk substance only if it "meets an applicable USP or NF monograph, it's a component of an FDA-approved drug product when no monograph exists, or it's on FDA's 503A Bulks List when neither of the first two applies."

Maximus sells none of those seven. Its BPC-157 articles are, if anything, harder on the molecule than its competitors' product pages are soft: "I would not talk about BPC-157 like the human outcome data is settled. It is not." They cite the orthopaedic review finding 35 of 36 included studies were preclinical. A company under no commercial pressure to be fair about a molecule was fair about it.

Which is what makes the oxytocin product the difficult part of this review rather than a routine one. The same organisation that can explain why a compounded peptide needs a monograph, a component relationship or a place on the bulks list, and that removed four sentences FDA objected to, launched a product whose evidence is a study with no control arm, no measured drug level, non-responders removed from the percentages, and a marketed dose twice the one analysed.

The standard exists inside this company. It is being applied unevenly, and the newest, most heavily promoted product is where it is applied least — which is a claim outrunning its evidence written by people who demonstrably know the difference.